HomeCompareSAG vs PFE

SAG vs PFE: Dividend Comparison 2026

SAG yields 198.02% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SAG wins by $112.65M in total portfolio value
10 years
SAG
SAG
● Live price
198.02%
Share price
$1.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$112.70M
Annual income
$56,534,499.65
Full SAG calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — SAG vs PFE

📍 SAG pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSAGPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SAG + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SAG pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SAG
Annual income on $10K today (after 15% tax)
$16,831.68/yr
After 10yr DRIP, annual income (after tax)
$48,054,324.70/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, SAG beats the other by $48,032,004.80/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SAG + PFE for your $10,000?

SAG: 50%PFE: 50%
100% PFE50/50100% SAG
Portfolio after 10yr
$56.37M
Annual income
$28,280,379.18/yr
Blended yield
50.17%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

SAG
No analyst data
Altman Z
3.8
Piotroski
6/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SAG buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSAGPFE
Forward yield198.02%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$112.70M$49.6K
Annual income after 10y$56,534,499.65$26,258.71
Total dividends collected$106.15M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SAG vs PFE ($10,000, DRIP)

YearSAG PortfolioSAG Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$30,502$19,801.98$9,153$693.39+$21.3KSAG
2$89,086$56,448.56$8,593$849.25+$80.5KSAG
3$249,403$154,080.96$8,336$1,066.78+$241.1KSAG
4$670,003$403,142.26$8,437$1,384.80+$661.6KSAG
5$1,729,066$1,012,162.66$9,013$1,875.40+$1.72MSAG
6$4,291,289$2,441,188.37$10,306$2,680.72+$4.28MSAG
7$10,253,990$5,662,310.92$12,820$4,101.38+$10.24MSAG
8$23,616,660$12,644,890.45$17,673$6,826.70+$23.60MSAG
9$52,487,868$27,218,041.68$27,543$12,591.86+$52.46MSAG
10$112,696,518$56,534,499.65$49,560$26,258.71+$112.65MSAG

SAG vs PFE: Complete Analysis 2026

SAGStock

SAG Holdings Limited, through its subsidiaries, distributes and sells automotive and industrial spare parts in the Asia Pacific, the Middle East, Europe, Africa, and the Americas. It operates in two segments, On-Highway Business and Off-Highway Business. The On-Highway Business segment supplies genuine original equipment manufacturer (OEM) and aftermarket parts, engine and chassis parts, wear and tear parts, body parts, and spare parts and lubricants for use in passenger and commercial vehicles. This segment serves resellers, such as distributors and dealers of automotive parts, retailers, workshops, end-users, and fleet owners. The Off-Highway Business segment supplies a range of filters, batteries, lubricants, components, and industrial spare parts for internal combustion engines for various sectors, including marine, energy, mining, construction, agriculture, and oil and gas. This segment serves distributors and dealers of industrial parts that are resold to workshops, industrial manufacturing facilities, shipyards, and heavy-duty transport fleet owners. The company also manufactures and distributes automotive spare parts and lubricants under the REV-1, VETTO, NUTEQ, GENTEQ, and SUNBLADE brands. In addition, it offers its products through retail outlets. The company was incorporated in 2022 and is based in Singapore. SAG Holdings Limited is a subsidiary of Soon Aik Global Pte Ltd.

Full SAG Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this SAG vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SAG vs SCHDSAG vs JEPISAG vs OSAG vs KOSAG vs MAINSAG vs JNJSAG vs MRKSAG vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.